Cover Image

MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling

Androgen deprivation therapy (ADT) is the main therapeutic option for advanced prostate cancer (PCa). After initial regression, most tumors develop into castration-resistant PCa (CRPC). Previously, we found the Mediator complex subunit MED15 to be overexpressed in CRPC and to correlate with clinical...

Full description

Saved in:
Bibliographic Details
Main Authors: Offermann, Anne (Author) , Duensing, Stefan (Author)
Format: Article (Journal)
Language:English
Published: 2017
In: OncoTarget
Year: 2017, Volume: 8, Issue: 5, Pages: 7964-7976
ISSN:1949-2553
DOI:10.18632/oncotarget.13860
Online Access:Resolving-System, kostenfrei, Volltext: http://dx.doi.org/10.18632/oncotarget.13860
Verlag, kostenfrei, Volltext: http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=13860&path[]=44164
Get full text
Author Notes:Anne Offermann, Ignacija Vlasic, Isabella Syring, Wenzel Vogel, Christian Ruiz, Tobias Zellweger, Cyrill A. Rentsch, Susanne Hagedorn, Jochen Behrends, Michael Nowak, Axel Merseburger, Lukas Bubendorf, Jutta Kirfel, Stefan Duensing, Zaki Shaikhibrahim, Sven Perner, Anne Offermann, Ignacija Vlasic, Isabella Syring, Wenzel Vogel, Christian Ruiz, Tobias Zellweger, Cyrill A. Rentsch, Susanne Hagedorn, Jochen Behrends, Michael Nowak, Axel Merseburger, Lukas Bubendorf, Jutta Kirfel, Stefan Duensing, Zaki Shaikhibrahim, Sven Perner
Description
Summary:Androgen deprivation therapy (ADT) is the main therapeutic option for advanced prostate cancer (PCa). After initial regression, most tumors develop into castration-resistant PCa (CRPC). Previously, we found the Mediator complex subunit MED15 to be overexpressed in CRPC and to correlate with clinical outcome. Therefore, we investigated whether MED15 is implicated in the signaling changes taking place during progression to CRPC. Immunohistochemistry (IHC) for MED15 on matched samples from the same patients before and after ADT reveals significantly increased MED15 expression after ADT in 72%.
Item Description:Published: December 10, 2016
Gesehen am 28.09.2018
Physical Description:Online Resource
ISSN:1949-2553
DOI:10.18632/oncotarget.13860

Similar Items